Ototoxicity of Long-Term α-Difluoromethylornithine for Skin Cancer Prevention.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 35620919.
- Also identified by DOI 10.1002/lary.30231 and PMC identifier 9701242.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Evaluate the effects of α-difluoromethylornithine (DFMO) on hearing thresholds as part of a randomized, double-blind, placebo-controlled trial. Subjects were randomized and assigned to the control (placebo) or experimental (DFMO) group. DFMO or placebo were administered orally (500 mg/m<sup>2</sup> /day) for up to 5 years. Subjects taking DFMO had, on average, increased hearing thresholds from baseline across the frequency range compared to subjects in the control group. Statistical analysis revealed this was significant in the lower frequency range. This randomized controlled trial revealed the presence of increased hearing thresholds associated with long-term DFMO use. As a whole, DFMO may help prevent and treat certain types of cancers; however, it can result in some degree of hearing loss even when administered at low doses. This study further highlights the importance of closely monitoring hearing thresholds in subjects taking DFMO. Laryngoscope, 133:676-682, 2023.
Medical subject headings
- Ototoxicity
- Hearing Loss
- Skin Neoplasms